Stryker Earnings Call Transcripts
Fiscal Year 2026
-
Leadership reaffirmed commitment to innovation and M&A, with strong recovery plans after a cyber incident. Full-year guidance is maintained, supported by robust demand, operational resilience, and a healthy capital backlog. Mako robotics and new product launches drive growth.
-
The meeting confirmed strong double-digit sales growth, major acquisitions, and a continued focus on innovation. All board nominees, auditor ratification, and executive compensation were approved. The five-year outlook projects sustained high growth through innovation and acquisitions.
-
Q1 2026 results were disrupted by a cyber incident, impacting sales and margins, but strong demand and operational recovery support reaffirmed full-year guidance for 8%-9.5% organic sales growth and $14.90-$15.10 adjusted EPS. M&A activity and new product launches are expected to drive growth.
Fiscal Year 2025
-
Delivered double-digit organic sales and EPS growth in 2025, driven by strong U.S. and international performance, robust product launches, and margin expansion. 2026 guidance anticipates 8%-9.5% organic sales growth and continued margin strength despite tariff headwinds.
-
The event outlined a refreshed strategy emphasizing digital solutions, operational excellence, and continued M&A in high-growth adjacencies. Guidance includes 150 bps margin expansion over three years, double-digit EPS growth, and a focus on smart hospital platforms and global expansion.
-
Delivered 9.5% organic sales growth and 11.1% adjusted EPS growth year-over-year, with strong U.S. and international performance across all segments. Raised full-year guidance, citing robust demand, margin expansion, and successful integration of recent acquisitions.
-
MedSurg and Neurotechnology continue to deliver double-digit organic growth, driven by innovation, targeted M&A, and strong execution across diverse business units. New product launches, digital integration, and expansion in areas like peripheral vascular and robotics are expected to sustain outperformance.
-
Delivered 10.2% organic sales growth and 11.4% adjusted EPS growth year-over-year, driven by robust demand across MedSurg, Neurotechnology, and Orthopaedics. Raised 2025 guidance, citing strong operational momentum, successful product launches, and effective tariff mitigation.
-
Leadership transition is seamless, with a continued focus on top-line growth, profitability, and M&A. Strong Q1 results, robust product pipeline, and effective tariff mitigation support ongoing margin expansion. Multi-year innovation cycles and recent acquisitions are expected to sustain growth.
-
The meeting confirmed strong sales growth, successful acquisitions, and robust innovation pipelines, with all management proposals and director nominees approved. Leadership transitions and digital healthcare initiatives were highlighted, and shareholder engagement addressed compensation and technology strategy.
-
Delivered 10.1% organic sales growth and 13.6% adjusted EPS growth year-over-year, driven by strong U.S. and international performance, robust demand for robotics and capital products, and successful integration of Inari Medical. Raised full-year guidance despite $200M tariff headwind.
-
Leadership is focused on sustaining growth through innovation, targeted M&A, and operational efficiency. Orthopedic and ASC markets are expanding, robotics adoption is rising, and portfolio shifts favor faster-growing segments. Margin expansion and global growth remain key priorities.
Fiscal Year 2024
-
Delivered over 10% organic sales growth and 15% adjusted EPS growth for 2024, with strong performance across all major segments and robust product launches. 2025 guidance calls for 8%-9% organic sales growth and $13.45-$13.70 adjusted EPS, excluding Inari, with continued margin expansion and strategic portfolio moves.
-
Q3 2024 saw 11.5% organic sales growth and 16.7% adjusted EPS growth, with double-digit gains across major segments and strong U.S. and international performance. Full-year guidance was raised to 9.5%-10% organic sales growth and $12.00-$12.10 adjusted EPS, supported by robust product demand, innovation, and recent acquisitions.
-
Strong first-half growth in orthopedics was driven by Mako and new product launches, with pricing pressure easing and share-taking strategies in place. Mako Spine and Shoulder are set for launch, while Pangea is expected to boost trauma growth in 2025. Robust capital spending and ASC demand support continued momentum.
-
Q2 2024 saw 9% organic sales growth, 10.6% higher adjusted EPS, and record Mako installations, with strong U.S. and international performance. Guidance for 2024 was raised, driven by robust demand, new product launches, and a healthy capital backlog.